The Trump administration is working on actions it can take without Congress to fight high drug prices, according to people who have attended listening sessions officials are holding on the issue.

It is unclear what exactly the administration will do or how consequential the measures will actually be. But the prospect of changes is leaving the pharmaceutical industry, a powerful lobbying force in Washington, facing some unpredictability.

One lobbyist said some attendees at listening sessions with HHS Secretary Tom Price went in expecting a "dog and pony show" but instead found a meeting that was "more substantive than expected," with Price and other top officials engaged and asking questions, though they did not tip their hand on what they are planning.